{"pmid":32403995,"title":"Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.","text":["Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.","Emerg Microbes Infect","Dong, Jianbo","Huang, Betty","Jia, Zhejun","Wang, Bo","Kankanamalage, Sachith Gallolu","Titong, Allison","Liu, Yue","32403995"],"journal":"Emerg Microbes Infect","authors":["Dong, Jianbo","Huang, Betty","Jia, Zhejun","Wang, Bo","Kankanamalage, Sachith Gallolu","Titong, Allison","Liu, Yue"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403995","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/22221751.2020.1768806","keywords":["covid-19","sars-cov-2","bi-specific antibody","humanized antibody","llama antibody","nanobody","tri-specific antibody"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845562699776,"score":9.490897,"similar":[{"pmid":32413276,"title":"Identification of Human Single-Domain Antibodies against SARS-CoV-2.","text":["Identification of Human Single-Domain Antibodies against SARS-CoV-2.","The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike protein, containing the receptor-binding domain (RBD) and S1 subunit involved in receptor engagement, is a potential therapeutic target. We describe the development of a phage-displayed single-domain antibody library by grafting naive complementarity-determining regions (CDRs) into framework regions of a human germline immunoglobulin heavy chain variable region (IGHV) allele. Panning this library against SARS-CoV-2 RBD and S1 subunit identified fully human single-domain antibodies targeting five distinct epitopes on SARS-CoV-2 RBD with subnanomolar to low nanomolar affinities. Some of these antibodies neutralize SARS-CoV-2 by targeting a cryptic epitope located in the spike trimeric interface. Collectively, this work presents a versatile platform for rapid antibody isolation and identifies promising therapeutic anti-SARS-CoV-2 antibodies as well as the diverse immogneic profile of the spike protein.","Cell Host Microbe","Wu, Yanling","Li, Cheng","Xia, Shuai","Tian, Xiaolong","Kong, Yu","Wang, Zhi","Gu, Chenjian","Zhang, Rong","Tu, Chao","Xie, Youhua","Yang, Zhenlin","Lu, Lu","Jiang, Shibo","Ying, Tianlei","32413276"],"abstract":["The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike protein, containing the receptor-binding domain (RBD) and S1 subunit involved in receptor engagement, is a potential therapeutic target. We describe the development of a phage-displayed single-domain antibody library by grafting naive complementarity-determining regions (CDRs) into framework regions of a human germline immunoglobulin heavy chain variable region (IGHV) allele. Panning this library against SARS-CoV-2 RBD and S1 subunit identified fully human single-domain antibodies targeting five distinct epitopes on SARS-CoV-2 RBD with subnanomolar to low nanomolar affinities. Some of these antibodies neutralize SARS-CoV-2 by targeting a cryptic epitope located in the spike trimeric interface. Collectively, this work presents a versatile platform for rapid antibody isolation and identifies promising therapeutic anti-SARS-CoV-2 antibodies as well as the diverse immogneic profile of the spike protein."],"journal":"Cell Host Microbe","authors":["Wu, Yanling","Li, Cheng","Xia, Shuai","Tian, Xiaolong","Kong, Yu","Wang, Zhi","Gu, Chenjian","Zhang, Rong","Tu, Chao","Xie, Youhua","Yang, Zhenlin","Lu, Lu","Jiang, Shibo","Ying, Tianlei"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413276","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.chom.2020.04.023","keywords":["cr3022","rbd","sars-cov-2","nanobody","single-domain antibody","trimeric interface"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319092551681,"score":103.6351},{"pmid":32375025,"title":"Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.","text":["Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.","Coronaviruses make use of a large envelope protein called spike (S) to engage host cell receptors and catalyze membrane fusion. Because of the vital role that these S proteins play, they represent a vulnerable target for the development of therapeutics. Here, we describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. Crystal structures of these VHHs bound to their respective viral targets reveal two distinct epitopes, but both VHHs interfere with receptor binding. We also show cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. These data provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronavirus outbreaks.","Cell","Wrapp, Daniel","De Vlieger, Dorien","Corbett, Kizzmekia S","Torres, Gretel M","Wang, Nianshuang","Van Breedam, Wander","Roose, Kenny","van Schie, Loes","Hoffmann, Markus","Pohlmann, Stefan","Graham, Barney S","Callewaert, Nico","Schepens, Bert","Saelens, Xavier","McLellan, Jason S","32375025"],"abstract":["Coronaviruses make use of a large envelope protein called spike (S) to engage host cell receptors and catalyze membrane fusion. Because of the vital role that these S proteins play, they represent a vulnerable target for the development of therapeutics. Here, we describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. Crystal structures of these VHHs bound to their respective viral targets reveal two distinct epitopes, but both VHHs interfere with receptor binding. We also show cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. These data provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronavirus outbreaks."],"journal":"Cell","authors":["Wrapp, Daniel","De Vlieger, Dorien","Corbett, Kizzmekia S","Torres, Gretel M","Wang, Nianshuang","Van Breedam, Wander","Roose, Kenny","van Schie, Loes","Hoffmann, Markus","Pohlmann, Stefan","Graham, Barney S","Callewaert, Nico","Schepens, Bert","Saelens, Xavier","McLellan, Jason S"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32375025","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cell.2020.04.031","keywords":["covid-19","mers","sars","sars-cov-2","nanobody"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496443613185,"score":84.942696},{"pmid":32366817,"pmcid":"PMC7198537","title":"A human monoclonal antibody blocking SARS-CoV-2 infection.","text":["A human monoclonal antibody blocking SARS-CoV-2 infection.","The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.","Nat Commun","Wang, Chunyan","Li, Wentao","Drabek, Dubravka","Okba, Nisreen M A","van Haperen, Rien","Osterhaus, Albert D M E","van Kuppeveld, Frank J M","Haagmans, Bart L","Grosveld, Frank","Bosch, Berend-Jan","32366817"],"abstract":["The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19."],"journal":"Nat Commun","authors":["Wang, Chunyan","Li, Wentao","Drabek, Dubravka","Okba, Nisreen M A","van Haperen, Rien","Osterhaus, Albert D M E","van Kuppeveld, Frank J M","Haagmans, Bart L","Grosveld, Frank","Bosch, Berend-Jan"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366817","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41467-020-16256-y","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496119603201,"score":74.83344},{"pmid":32404477,"title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.","text":["A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.","Neutralizing antibodies could be antivirals against COVID-19 pandemics. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. B38 and H4 block the binding between virus S-protein RBD and cellular receptor ACE2. A competition assay indicates their different epitopes on the RBD, making them a potential virus-targeting MAb-pair to avoid immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs. The RBD-B38 complex structure revealed that most residues on the epitope overlap with the RBD-ACE2 binding interface, explaining the blocking effect and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide a structural basis for rational vaccine design.","Science","Wu, Yan","Wang, Feiran","Shen, Chenguang","Peng, Weiyu","Li, Delin","Zhao, Cheng","Li, Zhaohui","Li, Shihua","Bi, Yuhai","Yang, Yang","Gong, Yuhuan","Xiao, Haixia","Fan, Zheng","Tan, Shuguang","Wu, Guizhen","Tan, Wenjie","Lu, Xuancheng","Fan, Changfa","Wang, Qihui","Liu, Yingxia","Zhang, Chen","Qi, Jianxun","Gao, George Fu","Gao, Feng","Liu, Lei","32404477"],"abstract":["Neutralizing antibodies could be antivirals against COVID-19 pandemics. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. B38 and H4 block the binding between virus S-protein RBD and cellular receptor ACE2. A competition assay indicates their different epitopes on the RBD, making them a potential virus-targeting MAb-pair to avoid immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs. The RBD-B38 complex structure revealed that most residues on the epitope overlap with the RBD-ACE2 binding interface, explaining the blocking effect and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide a structural basis for rational vaccine design."],"journal":"Science","authors":["Wu, Yan","Wang, Feiran","Shen, Chenguang","Peng, Weiyu","Li, Delin","Zhao, Cheng","Li, Zhaohui","Li, Shihua","Bi, Yuhai","Yang, Yang","Gong, Yuhuan","Xiao, Haixia","Fan, Zheng","Tan, Shuguang","Wu, Guizhen","Tan, Wenjie","Lu, Xuancheng","Fan, Changfa","Wang, Qihui","Liu, Yingxia","Zhang, Chen","Qi, Jianxun","Gao, George Fu","Gao, Feng","Liu, Lei"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404477","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1126/science.abc2241","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845583671298,"score":71.87327},{"pmid":32365751,"title":"The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor.","text":["The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor.","The COVID-19 disease has plagued over 200 countries with over three million cases and has resulted in over 200,000 deaths within 3 months. To gain insight into the high infection rate of the SARS-CoV-2 virus, we compare the interaction between the human ACE2 receptor and the SARS-CoV-2 spike protein with that of other pathogenic coronaviruses using molecular dynamics simulations. SARS-CoV, SARS-CoV-2, and HCoV-NL63 recognize ACE2 as the natural receptor but present a distinct binding interface to ACE2 and a different network of residue-residue contacts. SARS-CoV and SARS-CoV-2 have comparable binding affinities achieved by balancing energetics and dynamics. The SARS-CoV-2-ACE2 complex contains a higher number of contacts, a larger interface area, and decreased interface residue fluctuations relative to the SARS-CoV-ACE2 complex. These findings expose an exceptional evolutionary exploration exerted by coronaviruses toward host recognition. We postulate that the versatility of cell receptor binding strategies has immediate implications for therapeutic strategies.","Viruses","Brielle, Esther S","Schneidman-Duhovny, Dina","Linial, Michal","32365751"],"abstract":["The COVID-19 disease has plagued over 200 countries with over three million cases and has resulted in over 200,000 deaths within 3 months. To gain insight into the high infection rate of the SARS-CoV-2 virus, we compare the interaction between the human ACE2 receptor and the SARS-CoV-2 spike protein with that of other pathogenic coronaviruses using molecular dynamics simulations. SARS-CoV, SARS-CoV-2, and HCoV-NL63 recognize ACE2 as the natural receptor but present a distinct binding interface to ACE2 and a different network of residue-residue contacts. SARS-CoV and SARS-CoV-2 have comparable binding affinities achieved by balancing energetics and dynamics. The SARS-CoV-2-ACE2 complex contains a higher number of contacts, a larger interface area, and decreased interface residue fluctuations relative to the SARS-CoV-ACE2 complex. These findings expose an exceptional evolutionary exploration exerted by coronaviruses toward host recognition. We postulate that the versatility of cell receptor binding strategies has immediate implications for therapeutic strategies."],"journal":"Viruses","authors":["Brielle, Esther S","Schneidman-Duhovny, Dina","Linial, Michal"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32365751","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.3390/v12050497","keywords":["ace2","sars-cov-2","coronavirus evolution","molecular dynamics","protein-protein complex","virus-host interactions"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496175177728,"score":67.259094}]}